



6/16/02
PATENTS
#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

O'Reilly et al.

Serial No. 10/042,347

Filed: January 11, 2002

For: Nucleic Acid Molecules Encoding
Endostatin Protein and Peptide
Fragments Thereof

)
)
)
) Art Unit: 1642
)
) Examiner: Sheela J. Huff

RECEIVED

AUG 15 2002

TECH CENTER 1600/2000

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

This Supplemental Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be required. However, if a first Office Action on the merits has issued, please consider this Information Disclosure Statement under 37 C.F.R. 1.97(c). The Commissioner is hereby authorized to charge the applicable fees, if any, to Deposit Account No. 11-0855.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on August 08, 2002


Jamie L. Greene – Reg. No. 32,467

AUTLIB02 867741



The citation of this information does not constitute an admission of priority or
that any cited item is available as a reference, or a waiver of any right the applicant may have
under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Jamie L. Greene
Reg. No. 32,467

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 05213-0880 (43170-249874)

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

 <p>Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>				Complete if Known		
				Application No.	10/042,347	
				Filing Date	01/11/2002	
				First Named Inventor	O'Reilly et al.	
				Group Art Unit	1642	
				Examiner Name	Sheela Jitendra Huff	
Sheet	1	of	6	Attorney Docket Number	05213-0880 (43170-249874)	
U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number ²	Kind Code ³ (if known)			
	1	60/80728		MIXSON, James A.	06/27/2000	

RECEIVED
AUG 15 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered
--------------------	--	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

AUG 13 2002
PATENT & TRADEMARK OFFICE
U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

6

Complete if Known

Application No. 10/042,347

Filing Date 01/11/2002

First Named Inventor O'Reilly et al.

Group Art Unit 1642

Examiner Name Sheela Jitendra Huff

Attorney Docket Number 05213-0880 (43170-249874)

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


AUG 15 2002

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	2	Author: Chapter 12: Vectors for Gene Therapy Publ: Current Protocols in Human Genetics	Title: Chapter 12: Vectors for Gene Therapy	Vol/Iss:	Pages: Date: 1997
	3	Author: BOUSSIF, O. et al. Publ: Proc. Natl. Acad. Sci. USA	Title: A versatile vector for gene and oligonucleotide transfer into cells in culture and <i>in vivo</i> : Polyethylenimine	Vol/Iss: 92	Pages: 7297-7301 Date: 08/1995
	4	Author: CALOS, MICHELE P. Publ: TIG	Title: The potential of extrachromosomal replicating vectors for gene therapy	Vol/Iss: 12 (11)	Pages: 463-466 Date: 11/1996
	5	Author: CHEN, P. et al. Publ: Science	Title: Genetic Mechanisms of Tumor Suppression by the Human p53 Gene	Vol/Iss: 250	Pages: 1576-1579 Date: 12/1990
	6	Author: CHENG, PI-WAN Publ: Human Gene Therapy	Title: Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin	Vol/Iss: 7	Pages: 275-282 Date: 02/10/1999
	7	Author: DARDIK, R. et al Publ: Eur J Biochem	Title: The structure of endothelial cell thrombospondin - Characterization of the heparin-binding domains	Vol/Iss: 168 (2)	Pages: 347-355 Date: 10/15/1998
	8	Author: DEBS, R.J. et al. Publ: The Journal of Biological Chemistry	Title: Regulation of Gene Expression <i>in Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor	Vol/Iss: 265 (18)	Pages: 10189-10192 Date: 06/25/1999

Examiner Signature		Date Considered
--------------------	--	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Complete if Known	
Substitute for Form 1449/A (7-97)				Application No. 10/042,347	
				Filing Date 01/11/2002	
				First Named Inventor O'Reilly et al.	
				Group Art Unit 1642	
				Examiner Name Sheela Jitendra Huff	
Sheet	3	of	6	Attorney Docket Number 05213-0880 (4370-249874)	

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	9	Author: DIXIT, V.M. et al. Publ: <u>Proc. Natl. Acad. Sci. USA</u>	Title: A monoclonal antibody against human thrombospondin inhibits platelet aggregation Vol/Iss: 82 Pages: 3472-3476 Date: 05/1985		
	10	Author: FAN et al. Publ: <u>Trends in Pharmacological Sciences</u>	Title: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Vol/Iss: 16 (2) Pages: 57-66 Date: 02/95		
	11	Author: FIDLER et al. Publ: <u>Cell</u>	Title: The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis Vol/Iss: 79(2) Pages: 185-188 Date: 10/21/94		
	12	Author: FUJIWARA, T. et al. Publ: <u>Cancer Research</u>	Title: Induction of Chemosensitivity in Human Lung Cancer Cells <i>in Vivo</i> by Adenovirus-mediated Transfer of the Wild-Type <i>p53</i> Gene Vol/Iss: 54 Pages: 2287-2291 Date: 05/01/199		
	13	Author: GOLDMAN, C.K. et al. Publ: <u>Nature Biotechnology</u>	Title: In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer Vol/Iss: 15 Pages: 462-466 Date: 05/1997		
	14	Author: HAWKINS, MICHAEL J. M.D. Publ: <u>Current Opinion in Oncology</u>	Title: Clinical trials of antiangiogenic agents Vol/Iss: 7 Pages: 90-93 Date: 1995		
	15	Author: KING, RALPH P. Jr. Publ: <u>Wall Street Journal</u>	Title: Novel Cancer Approach From Noted Scientist Hits Stumbling Block Vol/Iss: Pages: A1, A8 Date: 11/12/199		

Examiner Signature		Date Considered
--------------------	--	-----------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known
Sheet 4 of 6				Application No. 10/042,347
				Filing Date 01/11/2002
				First Named Inventor O'Reilly et al.
				Group Art Unit 1642
				Examiner Name Sheela Jitendra Huff
				Attorney Docket Number 05213-0880 (1170249874)

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), name of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
	16	Author: KOSFELD, M.D. et al. Title: Identification of a New Cell Adhesion Motif in Two Homologous Peptides from the COOH-terminal Cell Binding Domain on Human Thrombospondin Publ: <u>The Journal of Biological Chemistry</u> Vol/Iss: 268 (12) Pages: 8808-8814 Date: 1993			
	17	Author: LESOON-WOOD, L.A. et al. Title: Systemic Gene Therapy with p53 Reduces Growth and Metastases of a Malignant Human Breast Tumor in Nude Mice Publ: <u>Human Gene Therapy</u> Vol/Iss: 6 Pages: 395-405 Date: 04/1995			
	18	Author: MAIONE, T.E. et al. Title: Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity Publ: <u>Cancer Research</u> Vol/Iss: 51 Pages: 2077-2083 Date: 04/15/1999			
	19	Author: MARSHALL, ELIOT Title: Gene Therapy's Growing Pains Publ: <u>Science</u> Vol/Iss: 269 Pages: 1050-1055 Date: 08/25/1999			
	20	Author: O'REILLY et al. Title: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth Publ: <u>Cell</u> Vol/Iss: 88 Pages: 277-285 Date: 01/24/97			
	21	Author: PARK et al. Title: Development of liposome- and anti-HER2 immunoliposomeplasmid complexes for efficient and selective gene therapy Publ: <u>Proceedings of the American Association for Cancer Research</u> Vol/Iss: 38 Pages: 342 Date: 03/1997			
	22	Author: PASQUALINI, R. et al. Title: $\alpha\beta$ Integrins as receptors for tumor targeting by circulating ligands Publ: <u>Nature Biotechnology</u> Vol/Iss: 15 Pages: 542-546 Date: 06/1997			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

O P E R A T I O N
AUG 13 2002
P R E M I U M
P R I V A T E
S E R V I C E

Substitute for Form 1449/A/PATENT

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No. 10/042,347

Filing Date 01/11/2002

First Named Inventor O'Reilly et al.

Group Art Unit 1642

Examiner Name Sheela Jitendra Huff

Sheet

5

of

6

Attorney Docket Number

05213-0880 (43170-249874)

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				AUG 15 2002
	23	Author: PASQUALINI, R. et al. <u>Publ:</u> <u>Nature</u>	Title: Organ targeting <i>in vivo</i> using phage display peptide libraries	Vol/Iss: 380	Pages: 364-166	Date: 03/28/199
	24	Author: SAIKI et al. <u>Publ:</u> <u>Jpn. J. Cancer Research</u>	Title: Inhibition of Tumor Angiogenesis by a Synthetic Cell-adhesive Polypeptide Containing the Arg-Gly-Asp (RGD) Sequence of Fibronectin, Poly(RGD)	Vol/Iss: 81	Pages: 668-675	Date: 1990
	25	Author: SHEIKH et al. <u>Publ:</u> <u>Oncogene</u>	Title: Overexpression of p21WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines	Vol/Iss: 11	Pages: 1899-1905	Date: 1995
	26	Author: TANAKA, T. et al. <u>Publ:</u> <u>Nature Medicine</u>	Title: Viral vector-mediated transductions of a modified platelet factor 3 cDNA inhibits angiogenesis and tumor growth	Vol/Iss: 3	Pages: 437-442	Date: 04/1997
	27	Author: WEINSTAT-SASLOW, D.L. et al. <u>Publ:</u> <u>Cancer Research</u>	Title: Transfection of Thrombospondin 1 Complementary DNA into a Human Breast Carcinoma Cell Line Reduces Primary Tumor Growth, Metastatic Potential, and <i>Angiogenesis</i>	Vol/Iss: 54	Pages: 6504-6511	Date: 1994
	28	Author: XU, M. et al. <u>Publ:</u> <u>Molecular Genetics and Metabolism</u>	Title: In Vivo Gene Therapy with a Cationic Polymer Markedly Enhances the Antitumor Activity of Antiangiogenic Genes	Vol/Iss: 64	Pages: 001-005	Date: 1998
	29	Author: XU, M. et al. <u>Publ:</u> <u>Molecular Genetics and Metabolism</u>	Title: Gene Therapy with P53 and a Fragment of Thrombospondin 1 Inhibits Human Breast Cancer <i>in Vivo</i>	Vol/Iss: 63	Pages: 103-109	Date: 1998

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. See attached Kinds of U.S. Patent Documents. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

AUG 13 2002

PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

6

Complete if Known

Application No. 10/042,347

Filing Date 01/11/2002

First Named Inventor O'Reilly et al.

Group Art Unit 1642

Examiner Name Sheela Jitendra Huff

Attorney Docket Number 05213-0880 (43170-249874)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T
	30	Author: XU, M. et al. Publ: <u>Human Gene Therapy</u>	Title: Parenteral Gene Therapy with p53 Inhibits Human Breast Tumors <i>In Vivo</i> Through a Bystander Mechanism Without Evidence of Toxicity Vol/Iss: 8 Pages: 177-185 Date: 01/20/199		
	31	Author: ZABRENETZKY, V. et al. Publ: <u>Int. J. Cancer</u>	Title: EXPRESSION OF THE EXTRACELLULAR MATRIX MOLECULE THROMBOSPONDIN INVERSELY CORRELATES WITH MALIGNANT PROGRESSION IN MELANOMA, LUNG AND BREAST CARCINOMA CELL	Vol/Iss: 59 Pages: 191-195 Date: 1994	
	32	Author: ZHU, N. et al. Publ: <u>Science</u>	Title: Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice Vol/Iss: 261 Pages: 209-211 Date: 07/09/199		

RECEIVED

AUG 15 2002

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.